治疗转移性黑色素瘤的免疫检查点抑制剂诱发无菌性鼻窦炎。

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-09-13 DOI:10.1080/1750743x.2024.2399498

Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec

{"title":"治疗转移性黑色素瘤的免疫检查点抑制剂诱发无菌性鼻窦炎。","authors":"Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec","doi":"10.1080/1750743x.2024.2399498","DOIUrl":null,"url":null,"abstract":"Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.\",\"authors\":\"Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec\",\"doi\":\"10.1080/1750743x.2024.2399498\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743x.2024.2399498\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743x.2024.2399498","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

免疫介导的鼻窦炎很少被描述，很容易被漏诊。我们开展了一项全国性多中心回顾性研究，重点关注接受免疫检查点抑制剂（ICIs）治疗黑色素瘤的患者中出现的免疫介导的鼻窦炎症状。研究共纳入了 12 名患者（50% 为女性，中位年龄为 58 岁）。总体而言，临床旁评估、抗生素/抗组胺药治疗无效、使用免疫抑制剂和/或停用 ICI 后症状有所改善，以及同时存在多种免疫相关不良事件，均表明其病因为非感染性。认识到这种毒性对于限制诊断徘徊和适当治疗至关重要。然而，还需要进行更多的流行病学研究，以评估其作为一种潜在的免疫相关不良事件的发生率及其在接受 ICIs 治疗的患者中的预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.

Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.